Humana Inc. (HUM) Given Consensus Rating of “Buy” by Brokerages

Humana Inc. (NYSE:HUM) has been given an average rating of “Buy” by the twenty-two ratings firms that are currently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $221.39.

A number of equities research analysts have recently weighed in on HUM shares. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $256.00 price target on the stock in a research note on Monday, May 8th. Evercore ISI restated an “overweight” rating on shares of Humana in a research note on Monday, February 27th. Deutsche Bank AG started coverage on shares of Humana in a research note on Wednesday, April 5th. They issued a “hold” rating and a $216.00 price target on the stock. Cantor Fitzgerald raised their price target on shares of Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Wednesday, April 26th. Finally, Oppenheimer Holdings, Inc. started coverage on shares of Humana in a research note on Thursday, March 30th. They issued an “outperform” rating and a $236.00 price target on the stock.

Humana (NYSE:HUM) traded up 0.60% during trading on Monday, reaching $238.42. 1,303,328 shares of the company’s stock were exchanged. The firm has a market cap of $34.41 billion, a P/E ratio of 24.30 and a beta of 0.90. Humana has a 52-week low of $150.00 and a 52-week high of $238.42. The stock’s 50 day moving average price is $230.72 and its 200 day moving average price is $213.63.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, May 3rd. The insurance provider reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.55 by $0.20. The firm had revenue of $13.76 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 2.71% and a return on equity of 14.38%. During the same period in the prior year, the company posted $1.86 earnings per share. Equities research analysts anticipate that Humana will post $11.15 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 31st. Investors of record on Friday, June 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.67%. The ex-dividend date is Wednesday, June 28th. Humana’s payout ratio is currently 16.24%.

In related news, VP Timothy S. Huval sold 13,939 shares of Humana stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $225.86, for a total value of $3,148,262.54. Following the completion of the sale, the vice president now owns 23,639 shares of the company’s stock, valued at approximately $5,339,104.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce D. Broussard sold 118,231 shares of Humana stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $225.82, for a total transaction of $26,698,924.42. Following the completion of the sale, the chief executive officer now directly owns 171,170 shares of the company’s stock, valued at approximately $38,653,609.40. The disclosure for this sale can be found here. In the last three months, insiders sold 138,270 shares of company stock valued at $31,253,863. 0.80% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. increased its stake in Humana by 39.4% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 3,182 shares of the insurance provider’s stock valued at $649,000 after buying an additional 900 shares during the last quarter. Federated Investors Inc. PA increased its stake in Humana by 9.1% in the fourth quarter. Federated Investors Inc. PA now owns 7,399 shares of the insurance provider’s stock valued at $1,510,000 after buying an additional 616 shares during the last quarter. Credit Agricole S A increased its stake in Humana by 18.7% in the fourth quarter. Credit Agricole S A now owns 59,113 shares of the insurance provider’s stock valued at $12,061,000 after buying an additional 9,323 shares during the last quarter. Gardner Lewis Asset Management L P increased its stake in Humana by 4.6% in the fourth quarter. Gardner Lewis Asset Management L P now owns 103,909 shares of the insurance provider’s stock valued at $21,201,000 after buying an additional 4,616 shares during the last quarter. Finally, AMF Pensionsforsakring AB increased its stake in Humana by 9.7% in the fourth quarter. AMF Pensionsforsakring AB now owns 27,200 shares of the insurance provider’s stock valued at $5,550,000 after buying an additional 2,400 shares during the last quarter. 98.92% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://transcriptdaily.com/2017/06/25/humana-inc-hum-given-consensus-rating-of-buy-by-brokerages.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply